The number of affected people by asthma is rising to reach up to 339 million worldwide. Asthma defined as chronic airway inflammation. A natural substance called resveratrol, which is present in several plants, red wine, and grapes, has been researched for its potential anti-inflammatory, and antioxidant qualities, and to induce relaxation of airway smooth muscle. The current study investigated whether Resveratrol (RES) could lessen allergic asthma that ovalbumin (OVA) causes in rats. Current results revealed that RES improved significantly (P<0.05) allergic asthma attenuation by decreasing the number of infiltrated mononuclear cells in Bronchoalveolar Lavage Fluid (BALF) and non-significantly (P>0.05) the number of infiltrated mononuclear cells intraperitoneally. RES increased lung integrity by reducing Evans blue extravasation in the lung (P<0.05) and liver (P>0.05). Additionally, in the BALF, RES therapy reduced (P<0.05) inflammatory cytokines including interleukin-17 (IL-17) and interferon-gamma (IFN-γ). RES increases (P<0.05) the expression of Il10 gene in the spleen, which is associated with T-regulatory and anti-inflammatory processes in the immune system. Our findings showed that RES may reduce asthma by activating anti-inflammatory genes, restoring lung barrier integrity, and decreasing proinflammatory cytokines and infiltrating inflammatory cells.